HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz

Zulma G Vitezica; Brigitte Milpied; Christine Lonjou; Nicolas Borot; Terence Niel Ledger; Anne Lefebvre; Alain Hovnanian

doi:10.1097/QAD.0b013e3282f37812

HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz

AIDS. 2008 Feb 19;22(4):540-1. doi: 10.1097/QAD.0b013e3282f37812.

Authors

Zulma G Vitezica¹, Brigitte Milpied, Christine Lonjou, Nicolas Borot, Terence Niel Ledger, Anne Lefebvre, Alain Hovnanian

Affiliation

¹ INSERM, U563, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France.

PMID: 18301070
DOI: 10.1097/QAD.0b013e3282f37812

Abstract

HLA typing, demographic and immunological risk factors for nevirapine and efavirenz reactions were studied in a French cohort of HIV patients. Cases with isolated rash were significantly associated with HLA-DRB101 allele. No liver toxicity was observed and no association was detected with the percentage of CD4 T-cells. This study suggests that HLA-DRB101 allele plays an important role in susceptibility to cutaneous reactions associated with nevirapine and efavirenz in HIV patients.

Publication types

Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Alkynes
Anti-HIV Agents / adverse effects*
Benzoxazines / adverse effects*
Cyclopropanes
Drug Eruptions / genetics*
Female
HIV Infections / drug therapy*
HIV Infections / genetics
HLA-DR Antigens / genetics*
HLA-DRB1 Chains
Humans
Male
Middle Aged
Nevirapine / adverse effects*
Prospective Studies

Substances

Alkynes
Anti-HIV Agents
Benzoxazines
Cyclopropanes
HLA-DR Antigens
HLA-DRB1 Chains
HLA-DRB1*01 antigen
Nevirapine
efavirenz